Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population

QJM: An International Journal of Medicine

Volumn 107, Issue 8, 2014, Pages 623-633

  Stack, A G ^a,b,c   Mutwali, A I ^b   Nguyen, H T ^a,c   Cronin, C J ^a,c   Casserly, L F ^a,c   Ferguson, J ^c  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b LETTERKENNY GENERAL HOSPITAL   (Ireland)

^c UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFERRIN; BIOLOGICAL MARKER; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HEALTH SURVEY; HEMATOLOGY ANALYZER; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; SURVIVAL RATE; TRANSFERRIN SATURATION; AGE DISTRIBUTION; BLOOD; EPIDEMIOLOGY; LIFESTYLE; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX RATIO; SOCIOECONOMICS; UNITED STATES; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HEALTH SURVEYS; HEMOGLOBINS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; TRANSFERRIN; UNITED STATES; YOUNG ADULT;

EID: 84904898330     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu045     Document Type: Article

References (25)

1. Andrews NC. Disorders of iron metabolism. Chap 46. In: Handin RI, Lux SE, Stossel TP, eds, Blood: Principles & Practice of Hematology. 2nd edn. Philadelphia USA: Lippincott Williams & Wilkins, 2003:1399-433.
2. Cook JD. Clinical evaluation of iron deficiency. Semin Hematol 1982; 19:6-18.
3. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47(5 Suppl 3):S16-85.
4. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328:1616.
5. Pippard MJ. Detection of iron overload. Lancet 1997; 349:73.
6. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005; 143:522-36.
7. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and risk of coronary disease. N Engl J Med 1994; 330:1119-24.
8. Mainous AG III, Gill JM, Carek PJ. Elevated transferrin saturation and mortality. Ann Fam Med 2004; 2:133-8.
9. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 2007; 27:565-71.
10. Stevens RG, Jones DY, MicozziMS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319:1047-52.
11. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25:162-6.
12. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358:1405-9.
13. Rivers J, Garrahy P, Robinson W, Murphy A. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 1987; 113:216.
14. Centers for Disease Control and Prevention: The Third National Health and Nutrition Examination Survey (NHANES III 1988-1994) Reference Manuals and Reports. Bethesda, MD, National Center for Health Statistics, 1996 (CD-ROM).
15. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994, Linked Mortality File: Matching Methodology. Hyattsville, MD: US Department of Health and Human Services, CDC, 2005.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1-266.
17. Gunter EW, Lewis BG, Koncikowski SM. Laboratory Procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
18. Looker AC, Gunter EW, Johnson CL. Methods to assess iron status in various NHANES surveys. Nutr Rev 1995; 53:246-54.
19. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39:920-9.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
21. Brownlie TT, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004; 79:437-43.
22. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40:90-103.
23. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 2004; 65:2108-12.
24. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65:2279-89.
25. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18:924-30.